Sample requirement
Clinical utility/
Intended use Comments
FFPE tissue from
a. prostate biopsy, or
b. prostate tissue after RP
a. Categorize patients into
low/high risk to stratify
patients into surveillance
vs. treatment (and intensity
of treatment).
b. Post-prostatectomy for
patients with adverse
pathologic features to
guide whether surveillance,
adjuvant, or salvage
therapy may be warranted.
Evaluates mRNA expression
levels of 22 genes from
FFPE tissue.
Generates score from 0–1.0.
Tumor tissue from original
biopsy in neutral buffered
formalin prostatectomy
specimens not accepted
Biopsy-based likelihood
of adverse pathologic
features (grade group ≥3 or
extracapsular extension).
Identifies those who may
benefit from surveillance vs
treatment.
GPS ranges from 0–100
based on mRNA expression
of 17 genes across four
pathways.
FFPE tissue from:
a. prostate tumor biopsy or
b. prostatectomy specimens
Aggressiveness of cancer:
Provides 10-year risk of
metastasis aer definitive
therapy and disease-specific
mortality under conservative
management.
mRNA expression of cell
cycle progression genes
is used to calculate the
score. Clinical factors are
subsequently added for risk
assessment.
Requires tissue collected with
patented biopsy kit available
from MetaMark
Uses automated image
recognition technolog y to
determine likelihood of
Grade Group ≥2 or stage
≥T3b.
Expression of 8 proteins:
Uses automated image
recognition technolog y to
generate a score from 1–100
indicating aggressiveness of
prostate cancer.
for
by
